Abstract: The present disclosure discloses a multistage nanoreactor catalyst and preparation and application thereof, belonging to the technical field of synthesis gas conversion. The catalyst consists of a core of an iron-based Fischer-Tropsch catalyst, a transition layer of a porous oxide or porous carbon material, and a shell layer of a molecular sieve having an aromatization function. The molecular sieve of the shell layer can be further modified by a metal element or a non-metal element, and the outer surface of the molecular sieve is further modified by a silicon-oxygen compound to adjust the acidic site on the outer surface and the aperture of the molecular sieve, thereby inhibiting the formation of heavy aromatic hydrocarbons. According to the disclosure, the shell layer molecular sieve with a transition layer and a shell layer containing or not containing auxiliaries, and with or without surface modification can be prepared by the iron-based Fischer-Tropsch catalyst through multiple steps.

Abstract: The present invention is a process for dehydrating an alcohol to prepare corresponding olefin(s), comprising: (a) providing a feed (A) comprising at least an alcohol having at least 2 carbon atoms, and preferably at most 5 carbon atoms, or a mixture thereof optionally water, optionally an inert component, in a dehydration unit, (b) placing the feed (A) into contact with an acidic catalyst in a reaction zone of said dehydration unit at conditions effective to dehydrate at least a portion of the alcohol to make an olefin or a mixture of olefins having the same number of carbon atoms as the alcohol, (c) recovering from said dehydration unit an effluent (B) comprising : an olefin or a mixture of olefins, water, undesired by-products including aldehydes and lighter products resulting from degradation of said aldehydes under the conditions of step (b), optionally unconverted alcohol(s) if any, optionally the inert component, wherein, said feed (A)-providing step (a) comprises adding an effective amount

Abstract: A process for selectively producing 1-butene comprises combining at least one antifouling agent and at least one aluminum alkyl compound to form an antifouling feed stream, wherein bringing the antifouling agent into contact with the aluminum alkyl compound forms at least one antifouling agent co-catalyst in a first step. The antifouling agent co-catalyst may comprise a structure comprising a central aluminum molecule bound to an R1 group, an R2 group, and an R3 group. The process further comprises feeding the antifouling feed stream, a catalyst comprising at least one titanate compound, and ethylene into a reactor dimerize ethylene in a second step. The catalyst is ted as a stream separated from the antifouling feed stream. The feeds may be varied in real-time to adjust a ratio of the formed antifouling agent co-catalyst and residual aluminum alkyl compound or antifouling agent in the antifouling feed stream.

Abstract: A composition comprising a perfluoro-N2-phosphinylamidine chromium salt complex having Structure PFAHNPACr I: wherein Rf1 is a substituted phenyl group comprising alkyl groups at the 2 and 6 positions and at least one fluoro group or perfluoroalkyl group at the 3, 4, and/or 5 positions, R2 is a C1 to C30 organyl group, R4 and R5 are each independently a C1 to C30 organyl group, and CrXp is a chromium salt where X is a monoanion, and p is an integer from 2 to 6.

Abstract: Disclosed are processes for oligomerizing ethylene by contacting a catalyst system, ethylene, and optionally hydrogen to form an oligomer product in a reaction zone, wherein the catalyst system comprises: a chromium component comprising an N2-phosphinyl amidine chromium compound complex, an N2-phosphinyl formamidine chromium compound complex, and/or an N2-phosphinyl guanidine chromium compound complex, and an aluminoxane; wherein the aluminoxane is characterized by 400 MHz proton NMR in which: (a) the ratio of peaks found in the range of ?0.86 ppm to ?0.74 ppm to peaks found in a range of ?0.03 ppm to 0.07 ppm is less than or equal to 2.8:1; (b) the ratio of peaks found in the range of ?0.03 ppm to 0.025 ppm to peaks found in a range of 0.025 ppm to 0.07 ppm is less than or equal to 15:1; and/or (c) the ratio of peaks found in a range of ?0.86 ppm to ?0.78 ppm to peaks found in the range of ?0.78 ppm to ?0.74 ppm is less than or equal to 6.5:1.

Abstract: The present invention relates to layered double hydroxides (LDH) nanoparticles containing a non-polar compound of plant origin, which provide said non-polar compounds with higher stability and photodegradation resistance, in order to increase their shelf and storage life. Furthermore, it is described a simple and economical method for separating a non-polar compound from a plant material that contains it, as well as a method for selectively releasing the non-polar compound of plant origin contained in the LDH nanoparticles, with a high purity.

Abstract: A method for producing 1,2-dichloro-3,3,3-trifluoropropene according to the present invention includes the step of reacting 1,1,2,3,3-pentachloropropene with a fluorinating agent where hydrogen fluoride is used as the fluorinating agent.

Abstract: Processes for stabilizing chloropropenes by removing oxygen and/or water and adding substituted phenols as stabilizers.

Abstract: The present invention relates to a method for producing unsaturated aldehydes and unsaturated carboxylic acids. According to the present invention, a method for producing unsaturated aldehydes and unsaturated carboxylic acids which can impart activity and control temperature independently in fixed catalyst layer zones in a shell-and-tube reactor, thereby exhibiting improved yield and operation stability, is provided.

Abstract: A process for the preparation of a class of molecules, namely bicyclo[1.1.1]pentanes and derivatives thereof by reaction of [1.1.1]propellane with a variety of reagents under irradiation and/or in the presence of radical initiators to obtain bicyclo[1.1.1]pentanes asymmetrically substituted at position 1 and 3, which are useful as intermediates for the preparation of asymmetrically 1,3-disubstituted bicyclo[1.1.1]pentane derivatives and various physiologically active substances or materials containing these structures.

Abstract: Levulinic-capped estolides having improved physical properties that make them more desirable and suitable as bio-based industrial or commercial products are disclosed. The physical properties of the disclosed estolide compositions have surprisingly low pour points that are substantially lower than previously known estolide compounds and superior to petroleum-based compounds designed for similar applications.

Abstract: The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

Abstract: Provided are a compound represented by the following Formula I, or a solvate, stereoisomer, or pharmaceutically acceptable salt thereof, and a composition for preventing or treating hair loss, the compound including the compound as an active ingredient:

Abstract: In synthesis of a compound represented by the General Formula (1) or a salt thereof, nitrilotriacetic acid as its raw material is reacted with a dehydrating agent to allow dehydration, and the resulting nitrilotriacetic acid anhydride is reacted with a dialkylamine to obtain a reaction intermediate product. The reaction intermediate product is then similarly reacted with a dehydrating agent to allow dehydration, and the resulting reaction intermediate anhydride is reacted with a dialkylamine to synthesize a tetraalkylnitriloacetic acid diacetamide compound. In Formula (1), R1, R2, R3 and R4 independently represent the same or different hydrocarbon group, with the proviso that the total number of carbon atoms in the hydrocarbon groups R1, R2, R3, and R4 is 8 to 64.

Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

Abstract: Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection.

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Abstract: Methods of identification of inhibitors of calcium release-activated calcium (CRAC) channel and small molecule inhibitors of CRAC channel, including methods of their synthesis and pharmaceutical use, are disclosed.

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.

Abstract: A 5-methoxytryptophan and its derivatives are disclosed, wherein the 5-methoxytryptophan and its derivatives are represented by the following formula (I): wherein R1, R2, R3, R4, R5, and n are defined in the specification. In addition, the present invention also provides novel uses of the 5-methoxytryptophan and its derivatives for treating inflammatory-related disease and cancers.

Abstract: A method for the manufacture of a bis(ether anhydride) comprises contacting an N-substituted bis(ether phthalimide) with a base under conditions effective to ring open the imides to provide a ring-opened product; and contacting the ring-opened product with an acid under conditions effective to provide a composition comprising the bis(ether anhydride).

Abstract: Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.

Abstract: Provided are a compound represented by the following Formula I-1 or I-2, and a composition for preventing or treating dementia or Alzheimer's disease, the composition including the compound and a pharmaceutically acceptable carrier:

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: A tetradentate chelating monoquinoline derivative with a structure as shown in formula (I) is able to specifically chelate redox active metal ions like copper ions that are dis-regulated in neurodegenerative diseases (Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis), or copper accumulation disease like Wilson's disease. The binding constants of these derivatives for zinc are 6-10 orders of magnitude below that ones for copper, and these derivatives have a good capability of reducing an oxidative stress. The method for preparing the derivative is simple and the derivatives have good application prospects in manufacturing drugs for neurodegenerative diseases and diseases related to disorder of copper metabolism.

Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.

Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.

Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Abstract: The embodiments described herein generally relate to methods and chemical compositions of triazine-arylhydroxy-aldehyde condensates. In one embodiment, a triazine-arylhydroxy-aldehyde condensate is reacted with at alkoxylation agent to form alkoxylated triazine-arylhydroxy-aldehyde condensates.

Abstract: Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).

Abstract: Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same.

Abstract: The invention relates to the manufacture of a compound of formula (I) wherein R1 is defined as in the description and in the claims.

Abstract: The invention relates to a process for the production of 5-hydroxymethylfurfural from a feedstock comprising at least one sugar using a combination of at least one catalyst selected from the homogeneous Lewis acids, the heterogeneous Lewis acids and the heterogeneous bases and at least one homogeneous Brønsted acid catalyst selected from the families of the thioureas, the sulphonic acids and the phosphorus-containing organic compounds, alone or in a mixture, in the presence of at least one aprotic polar solvent, at a temperature comprised between 30° C. and 300° C., and at a pressure comprised between 0.1 MPa and 10 MPa.

Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.

Abstract: The present invention provides novel compounds and methods for treating, preventing or inhibiting hepatitis B virus (HBV).

Abstract: The present invention provides an organic compound represented by general formula [1] described in claims. In general formula [1], Ar1 and Ar2 are each independently selected from an aryl group and a heteroaryl group. In general formula [1], R1 to R3 are each a hydrogen atom or a substituent. R4 is an electron-withdrawing substituent. X1 is oxygen or sulfur. Y1 to Y3 are each independently selected from a carbon atom and a nitrogen atom.

Abstract: Disclosed are a retinoid compound, a preparation method therefor, intermediates thereof and an application thereof. The retinoid compound I of the present invention has a good tumor growth inhibition rate.

Abstract: Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): wherein Y is an oxygen atom or a sulfur atom; X1 and X2 are each independently C(Ra), the two (Ra)s are the same or different, and the two (Ra)s are joined together to form a first aryl ring; X3 and X4 are each independently C(Rb), the two (Rb)s are the same or different, and the two (Rb)s are joined to form a second aryl ring or a heteroaryl ring.

Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.

Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate are also disclosed.

Abstract: The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs).

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula 1a, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.

Abstract: Forms I and II of the mesylate salt of the compound of formula (I), a preparation methods thereof, a pharmaceutical composition containing the crystal forms, and the use of the crystal forms in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancer, in mammal, in particular in human. The crystal forms of the mesylate salt of the compound of formula (I) have good solubilities and high bioavailabilities in animals.

Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.